Skip to main content
O

Oh2biotherapeutics

This company develops algorithms for generating therapeutic monoclonal antibodies, particularly targeting GPCRs. Their technology aims to simplify the antibody development process for researchers seeking new protein therapeutics.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Features

  • This company develops algorithms for generating therapeutic monoclonal antibodies, particularly targeting GPCRs. Their technology aims to simplify the antibody development process for researchers seeking new protein therapeutics.
This profile is AI-generated and may contain inaccuracies.